Plain-English translation of NCT04117672 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing Salovum, an egg yolk powder enriched with a natural protein called antisecretory factor, to see if it can help people recover from severe traumatic brain injury. The medication is thought to reduce harmful brain swelling and inflammation that often occurs after a serious head injury. Researchers will compare the effects of this treatment against a placebo (an egg yolk powder without the active ingredient) in patients who are hospitalized with the most severe brain injuries.
Severe brain injuries cause dangerous swelling inside the brain that can lead to death or long-term disability. While this medication has shown promise in animal studies and early human cases, researchers need to conduct a careful clinical trial to confirm whether it truly helps people recover better.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either Salovum or a placebo while you are hospitalized in the intensive care unit being treated for your brain injury. Medical staff will monitor your recovery using the same brain monitoring equipment that is standard care for severe brain injuries. The study will track how well you recover over time compared to patients receiving the placebo.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
Sweden
Testing effectiveness
Sponsor
Peter Siesjö
Collaborators
Skane University Hospital, Lantmannen Medical AB
Enrollment target
~20 participants
Started
March 2020
Primary completion
December 2026
Age range
10 Years – 70 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Peter Siesjö, MD, PhD
Skane University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.